Citigroup Downgrades Bristol-Myers Squibb to Neutral, Lowers Price Target to $55

Benzinga · 10/25 15:25
Citigroup analyst Andrew Baum downgrades Bristol-Myers Squibb (NYSE:BMY) from Buy to Neutral and lowers the price target from $75 to $55.